HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Douglas G Mack Selected Research

Berylliosis

1/2021Beryllium-specific CD4+ T cells induced by chemokine neoantigens perpetuate inflammation.
1/2020A role for TNF-α in alveolar macrophage damage-associated molecular pattern release.
10/2018TLR9 and IL-1R1 Promote Mobilization of Pulmonary Dendritic Cells during Beryllium Sensitization.
6/2014Regulatory T cells modulate granulomatous inflammation in an HLA-DP2 transgenic murine model of beryllium-induced disease.
5/2014Identification of multiple public TCR repertoires in chronic beryllium disease.
8/2013Impaired function of CTLA-4 in the lungs of patients with chronic beryllium disease contributes to persistent inflammation.
7/2013Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease.
12/2012Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease.
11/2011Beryllium-specific CD4+ T cells in blood as a biomarker of disease progression.
10/2011Mutagenesis of beryllium-specific TCRs suggests an unusual binding topology for antigen recognition.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Douglas G Mack Research Topics

Disease

17Berylliosis
01/2021 - 04/2006
5Inflammation (Inflammations)
01/2021 - 09/2006
4Granuloma
01/2022 - 02/2008
3Hypersensitivity (Allergy)
01/2020 - 07/2013
3Lung Diseases (Lung Disease)
10/2018 - 06/2010
2Genetic Predisposition to Disease (Genetic Predisposition)
04/2010 - 11/2005
1Sarcoidosis (Schaumann Disease)
10/2021
1Autoimmune Diseases (Autoimmune Disease)
01/2020
1Chronic Obstructive Pulmonary Disease (COPD)
01/2019
1Pneumonia (Pneumonitis)
06/2014
1Disease Progression
11/2011
1Emphysema
12/2010
1Pulmonary Hypertension
10/2010
1Fibrosis (Cirrhosis)
06/2009
1Disease Susceptibility (Diathesis)
11/2005

Drug/Important Bio-Agent (IBA)

16BerylliumIBA
01/2021 - 11/2005
4HLA-DPw2 antigenIBA
01/2022 - 04/2010
4MetalsIBA
01/2020 - 10/2011
4AntigensIBA
07/2013 - 12/2010
4CytokinesIBA
11/2011 - 09/2006
3Biomarkers (Surrogate Marker)IBA
01/2019 - 10/2010
3HLA-DP Antigens (HLA-DP)IBA
06/2014 - 11/2005
2Peptides (Polypeptides)IBA
01/2020 - 07/2013
2Glutamic Acid (Glutamate)FDA Link
04/2010 - 11/2005
1HLA-DRB1 Chains (HLA DRB1)IBA
10/2021
1EpitopesIBA
10/2021
1ChemokinesIBA
01/2021
1ChitinasesIBA
01/2019
1Cytochrome P450 Family 1IBA
01/2019
1LigandsIBA
07/2013
1Infliximab (Remicade)FDA Link
12/2012
1Alanine (L-Alanine)FDA Link
10/2011
1AntibodiesIBA
12/2010
1pristane (pristan)IBA
12/2010
1Chemokine ReceptorsIBA
10/2010
1Interleukin-7 (Interleukin 7)IBA
10/2010
1HLA-DPB1 antigen (HLA DPB1)IBA
04/2010
1Amino AcidsFDA Link
11/2005

Therapy/Procedure

1Therapeutics
12/2012